Cowen & Co. Sticks to Their Hold Rating for Zafgen

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on Zafgen (NASDAQ: ZFGN). The company’s shares opened today at $6.50.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.0% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.

Zafgen has an analyst consensus of Moderate Buy, with a price target consensus of $20.

See today’s analyst top recommended stocks >>

Based on Zafgen’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.09 million. In comparison, last year the company had a GAAP net loss of $13.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways. Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi Syndrome, or PW craniopharyngioma-associated obesity.